Literature DB >> 19667099

Type I interferon (IFN alpha) acts directly on human memory CD4+ T cells altering their response to antigen.

Kathleen M E Gallagher1, Sarah Lauder, Ian W Rees, Awen M Gallimore, Andrew J Godkin.   

Abstract

Despite its use widely as a therapeutic agent, and proposed use as vaccine adjuvant, the effect of IFNalpha on T cell function is poorly understood. As a pleiotropic innate cytokine produced rapidly in response to pathogens, it is well placed to impinge on specific immune responses. The aim of this study was to examine the impact of IFNalpha on the function of human memory CD4(+) T cells using the recall Ags purified protein derivative, tetanus toxoid, and hemagglutinin. IFNalpha administered either in vivo or added exogenously in vitro tended to enhance proliferative responses of purified protein derivative-specific T cells in marked contrast to the other cognate populations whose responses were often diminished. Purifying the memory CD4(+)CD45RO(+) T cells confirmed IFNalpha acted directly on these cells and not via an intermediate. The T cells could be divided into two broad categories depending on how IFNalpha effected their responses to cognate Ag: 1) enhanced proliferation and a striking increase in IFNgamma-production compared with smaller increases in IL-10 (increased ratio of IFNgamma:IL-10), and 2) neutral or diminished proliferation coupled with a smaller increase in IFNgamma relative to the increase in IL-10 (reduced IFNgamma:IL-10 ratio). IFNalpha has a role in modifying memory T cell responses when they are exposed to cognate Ag and may be important in vaccination strategies designed to augment particular Th memory responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667099     DOI: 10.4049/jimmunol.0801607

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Escalating regulation of 5T4-specific IFN-γ+ CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy.

Authors:  Awen Gallimore; Andrew Godkin; Martin Scurr; Anja Bloom; Tom Pembroke; Rohit Srinivasan; Clare Brown; Kathryn Smart; Hayley Bridgeman; Mike Davies; Rachel Hargest; Simon Phillips; Adam Christian; Tom Hockey
Journal:  Cancer Immunol Res       Date:  2013-12       Impact factor: 11.151

Review 2.  Lupus nephritis: the evolving role of novel therapeutics.

Authors:  Brad H Rovin; Samir V Parikh
Journal:  Am J Kidney Dis       Date:  2014-01-07       Impact factor: 8.860

3.  Selective HDAC6 inhibition decreases early stage of lupus nephritis by down-regulating both innate and adaptive immune responses.

Authors:  J Ren; X Liao; M D Vieson; M Chen; R Scott; J Kazmierczak; X M Luo; C M Reilly
Journal:  Clin Exp Immunol       Date:  2017-10-16       Impact factor: 4.330

4.  Influenza-induced production of interferon-alpha is defective in geriatric individuals.

Authors:  David H Canaday; Naa Ayele Amponsah; Leola Jones; Daniel J Tisch; Thomas R Hornick; Lakshmi Ramachandra
Journal:  J Clin Immunol       Date:  2010-02-25       Impact factor: 8.317

5.  Type I IFN-dependent T cell activation is mediated by IFN-dependent dendritic cell OX40 ligand expression and is independent of T cell IFNR expression.

Authors:  Jonathan S Kurche; Catherine Haluszczak; Jennifer A McWilliams; Phillip J Sanchez; Ross M Kedl
Journal:  J Immunol       Date:  2011-12-07       Impact factor: 5.422

6.  The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity.

Authors:  Byron C Burnette; Hua Liang; Youjin Lee; Lukasz Chlewicki; Nikolai N Khodarev; Ralph R Weichselbaum; Yang-Xin Fu; Sogyong L Auh
Journal:  Cancer Res       Date:  2011-02-07       Impact factor: 12.701

Review 7.  Update on Lupus Nephritis.

Authors:  Salem Almaani; Alexa Meara; Brad H Rovin
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 8.237

8.  Human metapneumovirus keeps dendritic cells from priming antigen-specific naive T cells.

Authors:  Pablo F Céspedes; Pablo A Gonzalez; Alexis M Kalergis
Journal:  Immunology       Date:  2013-07       Impact factor: 7.397

Review 9.  Current and Emerging Therapies for Lupus Nephritis.

Authors:  Samir V Parikh; Brad H Rovin
Journal:  J Am Soc Nephrol       Date:  2016-06-09       Impact factor: 10.121

Review 10.  Induction Therapy for Lupus Nephritis: the Highlights.

Authors:  Isabelle Ayoub; Jessica Nelson; Brad H Rovin
Journal:  Curr Rheumatol Rep       Date:  2018-08-14       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.